Hypercholesterolemia, eligibility for lipid-lowering therapy and therapeutic success: Population-based study in a Portuguese urban population

European Journal of Endocrinology

Volumn 159, Issue 6, 2008, Pages 755-760

  Alves, Luis ^a,b   Azevedo, Ana ^a  

^a University of Porto   (Portugal)

^b Santo André de Canidelo Family Health Unit   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMMUNITY SAMPLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PORTUGAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; URBAN POPULATION; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; HEALTH SURVEY; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PORTUGAL; RISK FACTORS; URBAN POPULATION;

EID: 58149333745     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0487     Document Type: Article

References (29)

1. Direcção-Geral da Saúde. Risco de Morrer em Portugal, 2001. DSIA Divisão de Epidemiologia 2003 29, 45.
2. Instituto Nacional de Estatística. Estatísticas demográficas 2005. Instituto Nacional de Estatistica, 2007 14.
3. Gould AL, Davies GM, Alemao E, Yin DD & Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clinical Therapeutics 2007 29 778-794.
4. O'Regan C, Wu P, Arora P, Perri D & Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121 000 patients. American Journal of Medicine 2008 121 24-33.
5. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA & Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Journal of the American Medical Association 2003 290 502-510.
6. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Hermann-Lingen C, Hoes A, Humphries S, Knapton M, Perk K, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J & Zamorano JL. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007 194 1-45.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H & Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 1837-1847.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497.
9. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, Solanas P, Cordón F, Ramos R, Sala J, Masiá R & Kannel WB. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. Journal of Epidemiology and Community Health 2003 57 634-638.
10. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amovyel P & Dallongeville J. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study European Heart Journal 2003 24 1903-1911.
11. Laurier D, Nguyen PC, Cazelles B & Segond P. Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group. Journal of Clinical Epidemiology 1994 47 1353-1364.
12. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW, Ruilope LM, Rosenthal T & Chatellier G. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. Journal of Hypertension 2002 20 1973-1980.
13. Menotti A, Puddu PE & Land M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. European Heart Journal 2000 21 365-370.
14. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L & Graham I. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003 24 987-1003.
15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergemen O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk K, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T & Wood D. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 2003 10 S1-S10.
16. Ramos E, Lopes C & Barros H. Investigating the effect of non-participation using a population-based case-control study on myocardial infarction. Annals of Epidemiology 2004 14 437-441.
17. Allain CC, Poon LS, Chan CS, Richmond W & Fu PC. Enzymatic determination of total serum cholesterol. Clinical Chemistry 1974 20 470-475.
18. Bucolo G & David H. Quantitative determination of serum triglycerides by the use of enzymes. Clinical Chemistry 1973 19 476-482.
19. Warnick GR & Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. Journal of Lipid Research 1978 19 65-76.
20. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
21. Sans S, Fitzgerald AP, Royo D, Conroy R & Graham I. Calibrating the SCORE cardiovascular risk chart for use in Spain. Revista Española de Cardiología 2007 60 476-485.
22. Panagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I & Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic Journal of Cardiology 2007 48 55-63.
23. Costa J, Borges M, Oliveira E, Gouveia M & Carneiro AV. Incidence and prevalence of hypercholesterolemia in Portugal: a systemic review. Part II. Revista Portuguesa de Cardiologia 2003 22 683-702.
24. Getz L, Kirkengen AL, Hetlevik I, Romundstad S & Sigurdsson JA. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scandinavian Journal of Primary Health Care 2004 22 202-208.
25. Buitrago F. Canon-Barroso L, Diaz-Herrera N, Cruces-Muro E, Escobar-Fernandez M & Serrano-Arias JM. Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment. Revista Española de Cardiología 2007 60 139-147.
26. Van Ganse E, Laforest L, Burke T, Phatak H & Souchet T. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clinical Therapeutics 2007 29 1671-1681.
27. Gouveia M, Borges M, Costa J, Oliveira E, David C & Carneiro AV. Costs of illness due to hypercholesterolemia in Portugal. Revista Portuguesa de Cardiologia 2004 23 1037-1054.
28. Gouveia M, Borges M, Costa J & Carneiro AV. Burden of disease from hypercholesterolemia in Portugal. Revista Portuguesa de Cardiologia 2004 23 255-270.
29. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L & Boudreau G. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Archives of Internal Medicine 2007 167 2296-2303.